{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:29:20Z","timestamp":1789194560871,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiol Drug Saf"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1002\/pds.3781","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T22:18:18Z","timestamp":1428013098000},"page":"559-566","source":"Crossref","is-referenced-by-count":34,"title":["Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis"],"prefix":"10.1002","volume":"24","author":[{"given":"Yakun","family":"Lang","sequence":"first","affiliation":[{"name":"Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital; Jiangsu University; Zhenjiang 212002 Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Gong","sequence":"additional","affiliation":[{"name":"Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital; Jiangsu University; Zhenjiang 212002 Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute of Molecular Biology and Translational Medicine, The Affiliated People's Hospital; Jiangsu University; Zhenjiang 212002 Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"10.1002\/pds.3781-BIB0001|pds3781-cit-0001","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/A:1008823222574","article-title":"A review of health-related quality-of-life concepts and measures for Parkinson's disease","volume":"8","author":"Damiano","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1002\/pds.3781-BIB0002|pds3781-cit-0002","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","article-title":"Incidence and remaining lifetime risk of Parkinson disease in advanced age","volume":"72","author":"Driver","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/pds.3781-BIB0003|pds3781-cit-0003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","article-title":"Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai","volume":"365","author":"Zhang","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/pds.3781-BIB0004|pds3781-cit-0004","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/pds.3781-BIB0005|pds3781-cit-0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jama.1996.03540100073032","article-title":"Calcium channel blockers. Lessons learned from MIDAS and other clinical trials","volume":"276","author":"Chobanian","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/pds.3781-BIB0006|pds3781-cit-0006","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00003495-199957060-00001","article-title":"Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?","volume":"57","author":"Rodnitzky","year":"1999","journal-title":"Drugs"},{"key":"10.1002\/pds.3781-BIB0007|pds3781-cit-0007","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/pds.3781-BIB0008|pds3781-cit-0008","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson's disease","volume":"175","author":"Pasternak","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1002\/pds.3781-BIB0009|pds3781-cit-0009","doi-asserted-by":"crossref","first-page":"e98961","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/pds.3781-BIB0010|pds3781-cit-0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson's disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1002\/pds.3781-BIB0011|pds3781-cit-0011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1002\/pds.3781-BIB0012|pds3781-cit-0012","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium channel blocker use and risk of Parkinson's disease","volume":"25","author":"Simon","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1002\/pds.3781-BIB0013|pds3781-cit-0013","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008535","article-title":"Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials","volume":"9","author":"Rees","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/pds.3781-BIB0014|pds3781-cit-0014","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1002\/pds.3781-BIB0015|pds3781-cit-0015","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1002\/pds.3781-BIB0016|pds3781-cit-0016","unstructured":"Wells G Shea B O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses Http:\/\/www.Ohri.Ca\/programs\/clinical_epidemiology\/oxford.Asp"},{"key":"10.1002\/pds.3781-BIB0017|pds3781-cit-0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","article-title":"Quantitative methods in the review of epidemiologic literature","volume":"9","author":"Greenland","year":"1987","journal-title":"Epidemiol Rev"},{"key":"10.1002\/pds.3781-BIB0018|pds3781-cit-0018","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000054770","article-title":"Risk factors for Parkinson's disease: the leisure world cohort study","volume":"20","author":"Paganini-Hill","year":"2001","journal-title":"Neuroepidemiology"},{"key":"10.1002\/pds.3781-BIB0019|pds3781-cit-0019","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00702-004-0124-0","article-title":"Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease","volume":"111","author":"Forte","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1002\/pds.3781-BIB0020|pds3781-cit-0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1474-4422(07)70246-6","article-title":"Calcium, ageing, and neuronal vulnerability in Parkinson's disease","volume":"6","author":"Surmeier","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1002\/pds.3781-BIB0021|pds3781-cit-0021","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00001756-199503000-00009","article-title":"Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice","volume":"6","author":"Kupsch","year":"1995","journal-title":"Neuroreport"},{"key":"10.1002\/pds.3781-BIB0022|pds3781-cit-0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(96)00917-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level","volume":"741","author":"Kupsch","year":"1996","journal-title":"Brain Res"},{"key":"10.1002\/pds.3781-BIB0023|pds3781-cit-0023","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","article-title":"The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease","volume":"43","author":"Ilijic","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1002\/pds.3781-BIB0024|pds3781-cit-0024","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.pbb.2010.11.014","article-title":"Effects of t-type calcium channel blockers on a parkinsonian tremor model in rats","volume":"97","author":"Miwa","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1002\/pds.3781-BIB0025|pds3781-cit-0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by dj-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"10.1002\/pds.3781-BIB0026|pds3781-cit-0026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.neuropharm.2008.10.016","article-title":"Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation","volume":"56","author":"Li","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1002\/pds.3781-BIB0027|pds3781-cit-0027","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"Rejuvenation' protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1002\/pds.3781-BIB0028|pds3781-cit-0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-199306000-00011","article-title":"Parkinsonism unmasked by verapamil","volume":"16","author":"Garcia-Albea","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/pds.3781-BIB0029|pds3781-cit-0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/106002809502900113","article-title":"Extrapyramidal symptoms associated with calcium-channel blockers","volume":"29","author":"Daniel","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1002\/pds.3781-BIB0030|pds3781-cit-0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22616","article-title":"Dihydropyridine calcium channel blockers and the progression of parkinsonism","volume":"71","author":"Marras","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1002\/pds.3781-BIB0031|pds3781-cit-0031","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/01.wnl.0000344171.22760.24","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"72","author":"Ascherio","year":"2009","journal-title":"Neurology"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3781","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pds.3781\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T04:58:41Z","timestamp":1717822721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3781"}},"subtitle":["CCBS AND RISK OF PD"],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1002\/pds.3781","archive":["Portico"],"relation":{},"ISSN":["1053-8569"],"issn-type":[{"value":"1053-8569","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,2]]}}}